UPDATE: Barrington Research Initiates Opko Health at Outperform on Pipeline Outlook

Barrington Research initiated coverage on Opko Health

with an Outperform rating and a $6 price target. Barrington Research commented, "We are initiating coverage of Opko Health, Inc. (OPK) with an OUTPERFORM rating and $6 target based on our belief that OPK's experienced management team led by multi‐billionaire Dr. Phillip Frost and long‐term business partner Dr. Jane Hsaio, will commercialize several billion dollar product lines. The OPK team has successfully acquired, licensed and developed technologies that we believe will ultimately be transformative to medicine." Opko Health closed at $4.42 on Friday.